July 2 2021 | Targeted Therapies in Oncology

Combining Camrelizumab, Chemotherapy Leads to Survival Benefit in Esophageal Squamous Cell Carcinoma

July 23, 2021

Clinical Articles

The frontline combination of camrelizumab and chemotherapy resulted in improved overall survival and progression-free survival and a manageable safety profile compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

Olaparib Improves Disease–Free Survival in Early HER2-Negative Breast Cancer

July 20, 2021

Clinical Articles

Patients who recived olaparib after a median follow-up of 2.5 years revealed a 42% reduction in invasive disease–free survival, including local and metastatic recurrence of breast cancer, other new cancers, and death due to any cause.

Adding 177Lu-PSMA-617 to Standard of Care Significantly Prolongs Survival in mCRPC

July 20, 2021

Clinical Articles

In patients with progressive prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer receiving treatment in the phase 3 VISION trial, the addition of the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death versus SOC alone.

Unique Immunotherapy Combos Evaluated in Advanced Melanoma

July 20, 2021

Special Reports

Immune-checkpoint inhibitor therapy, involving anti–CTLA-4 and anti–PD-1/ PD-L1 agents, has transformed the treatment of melanoma. Nonetheless, even with combination anti–PD-1 and anti–CTLA-4 therapy, nearly 50% of patients die of their disease at 5 years.